Definium Therapeutics, Inc. Definium Therapeutics, Inc.

Definium Therapeutics, Inc.

DFTX

Ранг среди акций #3487
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm... Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Цена акции
$36.08
Рыночная капитализация
$4.85B
Изменение (1 день)
1.65%
Изменение (1 год)
240.37%
Страна
US
Торговля Definium Therapeutics, Inc. (DFTX)

Категория

Healthcare
История цены акций Definium Therapeutics, Inc. (DFTX)
Наивысшая цена закрытия: $10.57 2024-04-01

Наименьшая цена закрытия: $4.87 2020-03-01
История цены акций Definium Therapeutics, Inc. с 2020 по 2026
Годовая динамика цены акций
Год Результативность
2024 205.04%
2023 33.53%
2022 -89.94%
2021 -40.17%
2020 0.00%
Цена акций похожих компаний или конкурентов
Компания Цена акций Изменение 1г% Страна
$536.13 25.72%
US
$200.12 645.31%
US
$137.83 -3.78%
AU
$291.76 2.51%
BE
$880.01 8.09%
NL